2023
Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.Peer-Reviewed Original ResearchImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyInhibitor therapyPulmonary toxicityEosinophilic asthmaAirway diseaseImmune related adverse eventsPD-1 inhibitor pembrolizumabSevere eosinophilic asthmaRelated adverse eventsICI therapyInhibitor pembrolizumabPD-1Benign courseTreatment cessationFatal complicationCase reportAdverse eventsSarcoidosisTherapyPneumonitisAirwayPatientsToxicityAsthma
2020
657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma
Saberian C, Fa’ak F, Tayar J, Buni M, Kim S, Lu H, Suarez-Almazor M, Gruschkus S, Daher M, Ludford K, Johnson D, Abdel-Wahab N, Diab A. 657 Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: a394-a394. DOI: 10.1136/jitc-2020-sitc2020.0657.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsIL-6R blockadeEfficacy of immune checkpoint inhibitorsMedian timeAdverse eventsIL-6RAnti-programmed cell death-1 antibodyImmune checkpoint inhibitor infusionsImmune mediated adverse eventsOverall tumor response ratePre-existing autoimmune diseaseInterleukin-6Interleukin-6 receptor blockadeClinical Disease Activity IndexICI-treated patientsTumor response rateMedian CRP levelsProspective clinical trialMinimal disease activityRelated adverse eventsDisease activity indexIrAE managementCheckpoint inhibitorsInterleukin-6 receptorMedian dose
2018
TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis.
Kim S, Shannon V, Sheshadri A, Kantarjian H, Garcia-Manero G, Im J, Ravandi F, Naing A, Futreal A, Daver N. TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis. Journal Of Clinical Oncology 2018, 36: 204-204. DOI: 10.1200/jco.2018.36.5_suppl.204.Peer-Reviewed Original ResearchAcute myeloid leukemiaBronchial alveolar lavageMyelodysplastic syndrome patientsCD4+ cellsImmune related adverse eventsMyelodysplastic syndromeCell subsetsImmune checkpoint inhibitor (ICI)-based therapyPneumonitis groupCD4+ cell subsetsAnalyzed BAL fluidBronchial alveolar lavage fluidRegulatory T cellsRelated adverse eventsAlveolar lavage fluidLineage specific markersPD-1BAL fluidMyeloid leukemiaT cellsLeukemia patientsLung inflammationRisk stratificationAdverse eventsLavage fluid